Melola Discovery

← Melola Discovery

Open access Journal SINTA 1

Urine Periostin Level and Renal Function in Malignancy Patients Treated with High-Dose Cisplatine

Folia Medica Indonesiana · Vol. 60 No. 4 (2024) · pp. 310–316

DOI
10.20473/fmi.v60i4.63357
ISSN
2355-8393, 2599-056X
Published
2024-12-11
Publisher
Airlangga University
Language
en
License
creativecommons.org/licenses/by-nc-sa/4.0/

Abstract

Cisplatin has been used extensively as a cancer treatment. Nephrotoxicity, which is assessed by blood urea levels, blood creatinine, and estimated glomerular filtration rate (eGFR), is caused by cisplatin metabolites that build up in the kidneys. Because of these indicators' numerous flaws, optimal biological markers are required. One of the key mediators of inflammatory processes, such as kidney fibrosis and inflammation, is periostin. In cancer patients undergoing high-dose cisplatin therapy, the purpose of this study is to ascertain how urine periostin changes and how it relates to kidney function. This cross-sectional study was carried out at the National Center General Hospital of Cipto Mangunkusumo's medical hematology-oncology outer clinic and medical hematology-oncology ward on the eighth floor starting in November 2019 and ending when the minimum sample was obtained through consecutive sampling. Data was analyzed by IBM SPSS Statistics for Windows version 23.0 based on the research objective. Of the 37 responders, 70.3% were men, 29.7% were between the ages of 41 and 50, 78.4% were married, 59.5% had completed high school, 37.8% were employed, 59.5% had NPC, and 64.9% had a Karnofsky score of 80. Between before and one week following chemotherapy II, the respondents' blood creatinine and urea levels rose. The eGFR value has also decreased. Periostin levels, on the other hand, tended to rise one week following treatment III after declining during chemotherapy I and II (p value>0.05). Urine periostin levels and other kidney function indicators did not significantly correlate (p>0.05), according to the correlation test, and several domains had negative directions. The correlation coefficient values were modest (r = 0.017-0.254). There is a changing of urine periostin level of malignant patients receiving high dose cisplatin therapy which increase after the third chemotherapy. No significant correlation was found between periostin levels and kidney function in malignant patients with high-dose cisplatin therapy.

Keywords

Collaboration network of the authors

11 authors · 23 co-authorship links · 8 across different organisations

Hover or tap a name to highlight its co-authors. Double-click to open the author's page.

  • Rumah Sakit Umum Pusat Nasional Dr. Cipto Mangunkusumo
  • Universitas Airlangga
  • Diponegoro University
  • Different organisations
  • Same organisation
  • Affiliation unknown
  • Thicker line = more joint articles · bigger circle = more articles
Show as table
Co-authorOrganisationJoint articles
Aditia R.R.Rumah Sakit Umum Pusat Nasional Dr. Cipto Mangunkusumo1
Indra WijayaDiponegoro University1
Cosphiadi IrawanRumah Sakit Umum Pusat Nasional Dr. Cipto Mangunkusumo1
Sukamto KoesnoeRumah Sakit Umum Pusat Nasional Dr. Cipto Mangunkusumo1
Arifa MustikaUniversitas Airlangga1
Mochammad ThahaUniversitas Airlangga1

Affiliations come from OpenAlex; journal OAI-PMH metadata carries none. Authors without an OpenAlex ID are matched by name, which can merge or split people.

Metadata source: OpenAlex API (jurnal SINTA, ADR 0048) https://openalex.org/S4210179714, first harvested 19 Nov 2026, last seen 19 Nov 2026.
Original metadata (oai_dc)
<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"><dc:title xml:lang="en">Urine Periostin Level and Renal Function in Malignancy Patients Treated with High-Dose Cisplatine</dc:title><dc:creator>Harry Yusuf</dc:creator><dc:creator>Andhika Rachman</dc:creator><dc:creator>Maruhum Bonar Hasiholan Marbun</dc:creator><dc:creator>Hamzah Shatri</dc:creator><dc:creator>Putri Aliya Ahadini</dc:creator><dc:subject>periostin</dc:subject><dc:subject>urinary biomarkers</dc:subject><dc:subject>cisplatin nephrotoxicity</dc:subject><dc:subject>high-dose cisplatin</dc:subject><dc:subject>renal function</dc:subject><dc:subject>estimated glomerular filtration rate</dc:subject><dc:subject>creatinine</dc:subject><dc:subject>blood urea</dc:subject><dc:subject>non-small cell lung cancer</dc:subject><dc:subject>chemotherapy-induced kidney injury</dc:subject><dc:subject>renal fibrosis</dc:subject><dc:description xml:lang="en">Cisplatin has been used extensively as a cancer treatment. Nephrotoxicity, which is assessed by blood urea levels, blood creatinine, and estimated glomerular filtration rate (eGFR), is caused by cisplatin metabolites that build up in the kidneys. Because of these indicators' numerous flaws, optimal biological markers are required. One of the key mediators of inflammatory processes, such as kidney fibrosis and inflammation, is periostin. In cancer patients undergoing high-dose cisplatin therapy, the purpose of this study is to ascertain how urine periostin changes and how it relates to kidney function. This cross-sectional study was carried out at the National Center General Hospital of Cipto Mangunkusumo's medical hematology-oncology outer clinic and medical hematology-oncology ward on the eighth floor starting in November 2019 and ending when the minimum sample was obtained through consecutive sampling. Data was analyzed by IBM SPSS Statistics for Windows version 23.0 based on the research objective. Of the 37 responders, 70.3% were men, 29.7% were between the ages of 41 and 50, 78.4% were married, 59.5% had completed high school, 37.8% were employed, 59.5% had NPC, and 64.9% had a Karnofsky score of 80. Between before and one week following chemotherapy II, the respondents' blood creatinine and urea levels rose. The eGFR value has also decreased. Periostin levels, on the other hand, tended to rise one week following treatment III after declining during chemotherapy I and II (p value&gt;0.05). Urine periostin levels and other kidney function indicators did not significantly correlate (p&gt;0.05), according to the correlation test, and several domains had negative directions. The correlation coefficient values were modest (r = 0.017-0.254). There is a changing of urine periostin level of malignant patients receiving high dose cisplatin therapy which increase after the third chemotherapy. No significant correlation was found between periostin levels and kidney function in malignant patients with high-dose cisplatin therapy.</dc:description><dc:publisher>Airlangga University</dc:publisher><dc:date>2024-12-11</dc:date><dc:type>info:eu-repo/semantics/article</dc:type><dc:format>application/pdf</dc:format><dc:identifier>https://doi.org/10.20473/fmi.v60i4.63357</dc:identifier><dc:identifier>10.20473/fmi.v60i4.63357</dc:identifier><dc:source>Folia Medica Indonesiana; Vol 60 No 4 (2024); 310-316</dc:source><dc:source>2355-8393</dc:source><dc:source>2599-056X</dc:source><dc:language>en</dc:language><dc:relation>https://e-journal.unair.ac.id/FMI/article/download/63357/30866</dc:relation><dc:rights>https://creativecommons.org/licenses/by-nc-sa/4.0/</dc:rights></oai_dc:dc>